Aclaris registers $86.25 million of stock for initial public offering

Bookrunners Jefferies, Citigroup and William Blair to assist with sale

By Devika Patel

Knoxville, Tenn., Aug. 17 – Aclaris Therapeutics, Inc. will price its initial public offering of common stock with a 30-day greenshoe, according to a Form S-1 filed Monday with the Securities and Exchange Commission. The company has registered up to $86.25 million of stock for the deal.

Jefferies, Citigroup and William Blair are the bookrunners.

Proceeds will be used for clinical trials, research and development, working capital and other general corporate purposes.

The pharmaceutical company is based in Malvern, Pa. The company intends to list its common stock on the Nasdaq under the symbol “ACRS.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.